Systematic review found cannabis-based medicines reduced neuropathic pain in most but not all RCTs

Among 22 RCTs of cannabis-based medicines for neuropathic pain, 15 reported significant pain reductions for conditions including multiple sclerosis, spinal cord injuries, diabetic neuropathy, postherpetic neuralgia, HIV-associated neuropathy, and peripheral neuropathic pain. Positive outcomes were more common with personalized, adjusted dosing. Seven trials found no significant pain relief versus placebo, though some showed improvements in secondary outcomes like mood and sleep.

Systematic review of literature from January 2003 to December 2024 using Web of Science, PubMed, and MEDLINE. Identified 22 RCTs evaluating CT-3, THC, CBD, THC/CBD combinations, and cannabidivarin for neuropathic pain across multiple conditions.

Neuropathic pain is notoriously difficult to treat, and many patients do not respond to first-line medications. This comprehensive review shows that cannabis-based medicines can help, but the evidence is complicated by study limitations and variable outcomes.

The pattern of positive results with personalized dosing and negative results with fixed dosing suggests that cannabis-based pain treatment may require individualized approaches rather than standardized protocols, which has implications for both clinical practice and future trial design.

Reviewed studies had small sample sizes and short durations. High placebo response rates in pain trials reduce statistical power. Psychoactive effects of THC may unblind participants. Heterogeneity in cannabinoid types, doses, and conditions limits direct comparisons across studies.